继发性血栓性微血管病中的补体激活
本文综述继发性血栓性微血管病(TMA)中补体激活的作用。产后TMA、合并高血压急症的TMA及肾移植后新发TMA常携带补体基因致病性变异,应视为补体介导的TMA,管理依赖早期启动补体抑制。其他病因的继发性TMA通常与补体基因变异无关,治疗以去除诱因或治疗基础病为主;补体抑制剂可考虑用于严重或难治性继发性TMA。
要点
- 产后TMA、合并高血压急症的TMA及肾移植后新发TMA补体基因致病性变异患病率高,应视为补体介导的TMA。
- 这些补体介导的继发性TMA,最佳管理依赖早期启动补体抑制。
- 其他病因的继发性TMA通常与补体基因变异无关,治疗以去除诱因或治疗基础病为主。
核心结论
- 继发性TMA中补体激活参与发病,补体抑制剂与更好的结局相关,可考虑用于严重或难治性继发性TMA。
- 产后TMA、合并高血压急症的TMA及肾移植后新发TMA应视为补体介导的TMA,最佳管理依赖早期启动补体抑制。
- 其他病因的继发性TMA通常与补体基因变异无关,管理主要聚焦于去除诱因或治疗基础病。
研究设计与样本
- 本文为综述,总结继发性TMA管理的当前认识与未来方向。
主要发现
- 产后TMA、合并高血压急症的TMA及肾移植后新发TMA补体基因致病性变异患病率高,与原发性非典型溶血性尿毒症综合征中观察到的相似。
- 自身免疫病、造血干细胞移植、药物、感染等其他继发性TMA病因通常与补体基因变异无关。
- 日益增多的证据提示补体激活也参与这些疾病的病理生理。
临床怎么用
- 产后TMA、合并高血压急症的TMA及肾移植后新发TMA应视为补体介导的TMA,最佳管理依赖早期启动补体抑制。
- 其他病因的继发性TMA管理主要聚焦于去除诱因或治疗基础病。
- 补体抑制剂可考虑用于严重(危及生命或器官的TMA)或难治性继发性TMA,即尽管对基础病进行了充分管理仍严重或难治的患者。
局限性
- 原文指出,精心设计的试验仍有待进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Secondary thrombotic microangiopathies (TMAs) represent a heterogeneous group of diseases associated with a high risk of kidney failure and death despite available therapeutic strategies. Strong evidence implicates complement activation in the pathogenesis of secondary TMA, and emerging data increasingly suggest that pharmacological blockade of the complement improves the outcomes in patients with secondary TMA. Certain forms of secondary TMA, including postpartum TMA, TMA with coexisting hypertensive emergency and de novo TMA after kidney transplantation exhibit a high prevalence of pathogenic variants in complement genes, similar to those observed in primary atypical haemolytic uraemic syndrome. These conditions should be considered as complement-mediated TMA triggered by pregnancy or transplantation or in which severe hypertension represents a symptom rather than the aetiology of TMA. Their optimal management relies on early initiation of complement inhibition. Other aetiologies of secondary TMA (i.e. autoimmune diseases, haematopoietic stem cell transplantation, drugs, infections) are typically not linked with complement gene variants and their management primarily focuses on removal of the culprit trigger or treatment of the underlying condition. While well-designed trials are still awaited, a growing body of evidence suggests that complement activation is also involved in the pathophysiology of these diseases. Complement inhibitors, which have been associated with better outcomes, should be considered in patients with severe (life- or organ-threatening TMA) or refractory secondary TMA despite adequate management of the underlying condition. This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as a therapeutic strategy.
引用
- Morelle J, Caravaca-Fontan F, Fakhouri F, et al. Complement activation in secondary thrombotic microangiopathies. Nephrol Dial Transplant. 2025. PMID: 40372375. doi:10.1093/ndt/gfaf091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。